Stryker (SYK) Tops Q3 EPS by 73c

Stryker (NYSE: SYK) reported Q3 EPS of $2.14, $0.73 better than the analyst estimate of $1.41. Revenue for the quarter came in at $3.7 billion versus the consensus estimate of $3.41 billion.

"We are pleased to have returned to growth in the third quarter and delivered strong adjusted earnings and cash flow in a challenging environment," said Kevin A. Lobo, Chairman and Chief Executive Officer. "Our teams executed well in serving our customers, advancing innovations and preparing for the Wright Medical integration."

GUIDANCE:

While we are still recovering from the impacts of the COVID-19 pandemic, most of our businesses reported overall increased unit volume during the third quarter. However, due to the uncertain scope and duration of the pandemic, and uncertain timing of global recovery and economic normalization, we are unable to estimate the overall impacts on our operations and financial results, which could be material. Accordingly, we will not be providing fourth quarter or full-year organic sales growth or earnings guidance for 2020.

For earnings history and earnings-related data on Stryker (SYK) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c